NANJING, China, April 1, 2008 /Xinhua-PRNewswire/ -- Simcere Pharmaceutical Group (NYSE:SCR), a leading manufacturer and supplier of branded generic pharmaceuticals and manufacturer of the patented anti-cancer biotech product Endu in China, today announced its participation in Brean Murray, Carret & Co.'s Fourth Investor Tour of China being held from Monday, March 31, 2008 to Friday, April 4, 2008 in Beijing, Shenzhen and Shanghai.
Simcere's Chief Financial Officer Frank Zhao, will present in the Aries Boardroom of the Grand Hyatt Shanghai on Friday April 4, 2008 at 11:15 am Beijing/Hong Kong time.
A copy of Simcere's investor presentation will be available on the investor relations portion of the Company's Web site, located at http://www.simcere.com/ .
About Simcere Pharmaceutical Group Simcere Pharmaceutical Group (NYSE:SCRNYSE:Simcere) is a leading manufacturer and supplier of branded generic pharmaceuticals and manufacturer of the patented anti-cancer biotech product Endu in the rapidly growing China market. In recent years, Simcere has focused its strategy on the development of first- to-market generic and innovative pharmaceuticals, and has introduced a first- to-market generic stroke management medication under the brand name Bicun and an innovative anti-cancer medication under the brand name Endu. Simcere currently manufactures and sells more than 50 pharmaceutical products including antibiotics, anti-cancer medication and stroke management medication, and is the exclusive distributor of three additional pharmaceuticals that are marketed under its brand names. Simcere concentrates its research and development efforts on the treatment of diseases with high incidence and/or mortality rates and for which there is a clear demand for more effective pharmacotherapy such as cancer, strokes, osteoporosis and infectious diseases, and currently has more than 12 pipeline products. For more information about Simcere Pharmaceutical Group, please visit http://www.simcere.com/ .
For investor and media inquiries, please contact:
Email: In Nanjing:
Frank Zhao
Chief Financial Officer
Simcere Pharmaceutical
Tel: +86-25-8556-6666 x8818 In Beijing:
Wu Kejia
Brunswick Group
Tel: +86-10-6566-2256 In Hong Kong:
Joseph Lo
Brunswick Group
Tel: +852-3512-5000 In the United States:
Michael Guerin
Brunswick Group LLC
Tel: +1-212-333-3810
DATASOURCE: Simcere Pharmaceutical Group CONTACT: IR Team, ; or in Nanjing, Frank Zhao, Chief Financial Officer of Simcere Pharmaceutical, +86-25-8556-6666 x8818, or in Beijing, Wu Kejia, +86-10-6566-2256, or in Hong Kong, Joseph Lo, +852-3512- 5000, or in the United States, Michael Guerin, +1-212-333-3810, all of Brunswick Group, for Simcere Web Site: http://www.simcere.com/
|